Eli Lilly and Company / LLY

Equity | Generated Nov 13, 2026 11:31 PM EST

Current price	Daily move	Bid / Ask	Previous close
$1,439.99	+12.71 +0.89%	-/-	$1,427.28

Market	**NYSE**
Industry	**Pharmaceuticals**
Market data as of	**Nov 13, 2026 11:32 PM EST**

JW Intelligence Report

Complete | 3 of 3 sections | Nov 13, 2026 6:50 PM EST

JW Rank	Rank label	Confidence	IV percentile
69.1 / 100	Constructive	high	20 / 100

Model reference	Upside scenario	Risk reference	Wheel strategy fit
$1,428.00	$1,494.00	$1,385.00	49 / 100

Options stance	**bullish**
Tail-risk safety	**45 / 100**
JW Rank data coverage / as of	**100.0% | Nov 13, 2026 6:50 PM EST**

Key insight

Lilly Option Market Prices in Continued Upside Potential

Market read

The market for LLY options suggests continued bullish sentiment, driven by strong recent performance and positive news flow. Implied volatility is elevated but not extreme, indicating a balanced view of potential upside and downside risk. The term structure is flat, suggesting similar expected volatility across various expirations.

Strategy context

The current market environment favors long calls or bull call spreads for LLY. However, traders should be mindful of stretched valuations and potential profit-taking near resistance levels.

JW AI conclusions

Short- and medium-term model interpretation

AI context bias	**Bullish**
AI analysis updated	**Nov 13, 2026 2:20 PM EST**

Short-term scenario

Cautious long only on a pullback; do not chase $1,447. Preferred 1-3 week setup is a dip toward the prior close/intraday support zone, targeting the first Fibonacci extension, with a stop under recent support. If price never pulls back, skip the trade. Uncertainty is high: RSI is stretched, the stock is within about 1% of the 52-week high, and a failed breakout could retrace roughly one ATR quickly. This is not a recommendation to buy at the market.

Three-month outlook

Base case is modestly constructive but valuation-capped. Volume growth in Mounjaro and Zepbound, oral and new-indication progress, manufacturing buildout, and a still-bullish trend can support a grind toward the mid-$1,500s to low-$1,600s if estimates keep rising and the stock holds above roughly $1,333-$1,385. Street averages near the current price imply limited consensus upside from here unless guidance is raised again. Material downside risks include U.S. price erosion, oral competition versus Novo Nordisk, a slower Foundayo ramp, reimbursement or policy pressure, capacity delays, and multiple compression from a trailing P/E near 47. Uncertainty is high: three-month outcomes can gap on trial, regulatory, or pricing headlines, and recent momentum does not ensure continuation. Not investment advice.

Market sentiment

Recent investor posts lean cautiously bullish but are thin and noisy. Traders cite a breakout above a descending trendline, support near $1,253 and resistance near $1,600, and describe persistent bullish momentum with buy-on-momentum verdicts. Other commentary frames LLY as the GLP-1 leader near historical highs after the guidance raise, with informal near-term targets of $1,500-$1,600 and explicit risks around oral competition, pricing, capacity and coverage. Clinical discussion of orforglipron (ATTAIN-J/OSA versus earlier trials) is mixed-to-neutral, arguing results look broadly consistent after adjustments but are noisy. Counterposts flag uncertain short-term follow-through. Uncertainty: the X sample includes promotional spam, so sentiment is not a reliable signal and can reverse quickly near highs.

Supporting evidence


LLY's price has surged over 1% today, reaching a new 52-week high near $1460. | The stock is well above its key moving averages, with strong momentum indicators like RSI and MACD signaling bullish strength. | Recent positive news regarding clinical trial results for Mounjaro and Zepbound, as well as the company's expansion plans, has fueled investor optimism.

Risk watch

High valuation multiples could limit further upside potential. | Oral competition from Novo Nordisk poses a risk to Mounjaro's market share.

Enhanced price structure


45 trading days with volume, model levels and current technical reference bands



45 complete trading-session observations

JW Rank factors

Score, source coverage and interpretation for each decision factor



Decision summary

Primary model reads before the detailed indicator appendix

Momentum	Institutional flow	Structure	Volatility
strong_bull	Above MVWAP	Above 200D trend	medium

Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	**STRONG BULL | neutral | MACD accelerating**
Trend signal	**STRONG BULL**
RSI signal	**neutral**
RSI (7 / 14 / 21)	**70.74 / 69.72 / 67.93**
RSI velocity	**-0.03**
MACD line / signal / histogram	**57.16 / - / 53.71**
MACD acceleration	**0.37**
Stochastic K / D	**89.10 / 88.07**

Institutional footprints

Volume-weighted cost, price location and flow

Current read	**Above institutional MVWAP | Accumulation bias**
Institutional flow	**9.29**
20-day MVWAP	**$1,371.89**
Price vs 20-day MVWAP	**+4.96%**
Daily reference VWAP	**$1,437.64**
Price vs daily reference	**+0.16%**
Volume	**1.31M**

Structural context

Long-term trend and volatility boundaries

Current read	**Above 200-day trend | Positive macro velocity**
Macro velocity	**9.84**
20-day / 200-day SMA	**$1,356.24 / $1,109.32**
Bollinger range	**$1,216.10 - $1,496.39**
Bollinger position	**0.811**

Options and volatility intelligence


Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
21 / 100	20 / 100	101.59	150.16

Market regime	**COMPRESSION RISK**
Tail-risk regime	**NORMAL TAIL RISK**
Term structure	**flat**
Term slope	**+0.11 pts**
Skew read	**balanced**
Liquidity / quote coverage	**100.0%**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Nov 13, 2026 2:55 PM EST**
Options data quality	**Coverage 100.0%**

Option term structure

ATM implied-volatility curve by days to expiration



Upward-sloping ATM volatility term structure


EXPIRATION	DTE	ATM IV	STATE
2026-11-20	7	29.3%	-
2026-11-27	14	28.2%	-
2026-12-04	21	29.4%	-

Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit

Bear Call Spread reference

Short $1,480.00 | Long $1,500.00 | Width $20.00 | Net credit $4.83



Max profit $483.00 | Max loss -$1,517.00 | Break-even $1,484.83 | Per contract at expiry

Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	**2026-10-29**
Earnings IV-crush risk	**moderate**
Event IV premium	**1.11**
VIX	**19.11**
VVIX	**101.59**
SKEW index	**150.16**
Observation confidence	**high**
Option quote quality	**reliable**
Contracts observed	**102**
Contracts with quotes	**102**

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The market for LLY options suggests continued bullish sentiment, driven by strong recent performance and positive news flow. Implied volatility is elevated but not extreme, indicating a balanced view of potential upside and downside risk. The term structure is flat, suggesting similar expected volatility across various expirations.

Options context

Lilly Option Market Prices in Continued Upside Potential

Wheel context

The current market environment favors long calls or bull call spreads for LLY. However, traders should be mindful of stretched valuations and potential profit-taking near resistance levels.

Observed evidence

LLY's price has surged over 1% today, reaching a new 52-week high near $1460. | The stock is well above its key moving averages, with strong momentum indicators like RSI and MACD signaling bullish strength. | Recent positive news regarding clinical trial results for Mounjaro and Zepbound, as well as the company's expansion plans, has fueled investor optimism.

Principal risks to monitor

High valuation multiples could limit further upside potential. | Oral competition from Novo Nordisk poses a risk to Mounjaro's market share.

Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization	P/E (TTM)
$1.34T	**49.03**
ROE	Revenue growth
83.7%	**31.7%**
EPS growth	Operating margin
49.3%	**40.3%**
Net profit margin	Gross margin
31.9%	**-**
Free cash flow CAGR	Debt / equity
5.9%	**1.60**
Dividend yield	Beta
0.8%	**0.37**

52-week range

$850.51 - $1,453.00

Company or fund profile

Issuer identity and classification

Name	Market
Eli Lilly and Company	**NYSE**
Industry	Country
Pharmaceuticals	**US**
Currency	IPO date
USD	**1970-07-09**
Shares outstanding	52-week return
940.75M	**45.4%**
Book value per share	Revenue per share
$42.79	**$96.78**

Website	lilly.com

Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal

Nov 4, 2026 3:45 PM EST

Covered Call | 2026-11-06

At signal $1,422.74 | Current $1,439.99

SHORT **Option $1,425.00 B $14.30 / A $14.95**

Conservative | CR $14.63

Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	**$44.31**
ATR as % of price	**3.1%**
Volatility environment	**medium**
Current IV	**31.4%**
IV rank	**20 / 100**
IV percentile	**20 / 100**
Technical Snapshot IV source	**Private fundamentals snapshot**
Technical Snapshot IV observed at	**Nov 13, 2026 6:32 PM EST**

Technical health and risk radar

Derived indicator health and event context

Overall health	**77 / 100**
Trend health	**92 / 100**
Momentum health	**74 / 100**
Volatility health	**64 / 100**
Structure health	**69 / 100**
Earnings risk / date	**unknown | 2026-10-29**
Macro risk	**unknown**
Volatility risk	**medium**
Structure risk	**low**

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	**$1,356.24 / $1,241.08 / $1,109.32**
EMA (9 / 21)	**$1,409.53 / $1,356.59**
Bollinger upper / middle / lower	**$1,496.39 / $1,356.24 / $1,216.10**

Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
Bollinger %B	**0.811**
True high / low	**$1,449.64 / $1,419.77**
5-day true high / low	**$1,460.00 / $1,354.00**

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	9.845	**-**
SMA50	5.523	**-**
MVWAP20	9.290	**-**
MACD	0.374	**-**
RSI	-0.033	**-**
Volume	-57137.670	**-**
ATR	-1.217	**-**
T1	-	**56.87 / 1365.22 / 1460.00 / 1427.28**
T2	-	**57.32 / 1354.21 / 1440.47 / 1414.37**
T3	-	**56.04 / 1344.02 / 1438.88 / 1400.00**

Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	**$1,447.09**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Nov 13, 2026 2:55 PM EST**
Options data coverage	**100.0%**
SKEW regime	**HIGH TAIL RISK SKEW**
VVIX regime	**VVIX FALLING**
Front expiration / DTE	**2026-11-20 | 7 DTE**
Front at-the-money IV	**29.3%**
25-delta skew	**2.06**
Put / Call 25-delta	**$1,415.00 Delta -0.286 / $1,480.00 Delta 0.297**
Median option bid/ask spread	**17.9%**
Bid/ask spread	**-**
Contracts observed / quoted	**102 / 102**

Price context

Last Price: 1,447.09 | Bid: 1,446.63 | Ask: 1,447.38 | Previous Close: 1,427.28 | Change: 19.81 | Daily change: 1.39% | Update Time: 2026-11-13T14:55:41.739801-05:00 | Latest History Date: 2026-11-13 | Latest History Price: 1,447.09

Historical context

Trading-day sample: 60 sessions | First Date: 2026-08-21 | Latest Date: 2026-11-13 | Latest Price: 1,447.09 | Max Drawdown 60d Percent: -11.13%

Fundamental context

Current Iv Percent: 31.59% | Iv Rank: 21.26 | Iv Percentile: 20.32 | Next Earnings Date: 2026-10-29 | Ex Dividend Date: 2026-11-12

Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Generated Nov 13, 2026 11:31 PM EST. Jason Wheel Terms of Use and Privacy Policy apply. Copyright Jason Wheel Research LLC. All rights reserved.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	**jasonwheel.com**
Terms of Use	**jasonwheel.com / Terms**
Privacy Policy	**jasonwheel.com / Privacy**
Options Disclosure Document	**theocc.com / Options Disclosure Document**